comparemela.com

Latest Breaking News On - கார்ஸ்டன் பிஷ்ஷர் - Page 1 : comparemela.com

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Provided by Business Wire Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant MTX-COVAB shows excellent neutralizing activity against original and British variants; ready for clinical development New antibodies identified with picomolar neutralizing activity against South African variant Working with Serum Institute India, and prestigious academic partners in Austria, Brazil and South Africa for patient donations to identify additional best-in-class antibodies against all variants of concern Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7). Memo is now preparing MTX-COVAB for clinical evaluation.

Memo Therapeutics antibodies show efficacy against Covid-19 variants Startupticker ch

MTX-COVAB, a human-derived antibody against SARS-CoV-2, has shown efficacy against both the original virus as well as the UK variant.  Memo is now preparing MTX-COVAB for clinical evaluation. In addition, the company was able to identify a very promising antibody candidate against the South African variant. Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo Therapeutics can discover novel antibodies at high speed, efficiency and sensitivity derived from recovered patient samples. This approach has enabled the company to also identify a very promising antibody candidate against the South African variant (B.1.351).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.